Search results
Dr. Andrea Baines is the Medical Officer of the Division of Hematology Products at the U.S. Food and Drug Administration. She is an oncologist in Baltimore, Maryland. She received her MD and PhD from University of Michigan Medical School and she completed her residency at Johns Hopkins Bayview.
May 21, 2019 · “Metastatic triple-negative breast cancer is an aggressive and challenging disease to treat, especially after progression on initial standard-of-care treatment,” said Roy Baynes, MD, PhD, senior...
Jan 8, 2024 · Baynes holds a PhD from the University of Witwatersrand, where he also received his MMed (specialist registration), MB and BCh (Bachelor of Medicine and Surgery).
2 days ago · by Andrea Lobo September 30, 2024. Treatment with tavapadon as a fixed-dose single therapy significantly improved motor function in early stage Parkinson’s disease, according to top-line data from a completed Phase 3 trial. Full results from TEMPO-1 (NCT04201093) will be presented at future medical meetings and support regulatory submissions ...
Jan 8, 2024 · – GERMANY, Martinsried – CatalYm today announced the appointment of Dr. Roy Baynes to its Board as an Independent Director. The company also announced the appointments of Dr. Petros Grivas, Dr. Roy Herbst, and Prof. Andrea Necchi to its Scientific Advisory Board.
Jun 28, 2024 · Roy Baynes, MD, PhD, was instrumental in the development of pembrolizumab when he was CMO and Head of Clinical Development at Merck. In this Q&A, Dr Baynes sheds light on the strategy for developing pembrolizumab and how he’s translating that experience into his role at Eikon Therapeutics.
From March 2021 to August 2022, 669 patients were randomly assigned (darolutamide n = 446; placebo n = 223). At the primary cutoff date (June 7, 2024), darolutamide plus ADT significantly improved rPFS, reducing the risk of radiological progression or death by 46% versus placebo plus ADT (hazard ratio [HR], 0.54 [95% CI, 0.41 to 0.71]; P < .0001), with consistent benefits across subgroups ...
